Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 21,150 shares at $43.87 ($922K) on 2025-05-06, disclosed to the SEC on 2025-05-08.
Scheduled sale ($922k) by Chief Scientific Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $42.26 | 3,550 | $150K | 16.3% |
| 2 | $43.87 | 8,650 | $379K | 41.1% |
| 3 | $43.87 | 8,650 | $379K | 41.1% |
| 4 | $44.50 | 300 | $13K | 1.4% |
| Total | $43.61 avg | 21,150 | $922K | 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |